HEART.ST Real Heart
- Market cap
- SEK 142M
- P/E
- -
- P/B
- 1.60x
- ROE
- -56.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is HEART.ST undervalued?
Graham numberThe Graham number of Real Heart cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Real Heart fundamental analysis
No fundamental analysis for Real Heart yet.
Real Heart stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Real Heart
Scandinavian Real Heart AB (Publ) engages in the design and development of an artificial heart. The company develops Realheart TAH to treat advanced stage heart failure. It also develops RealVAD for pulsating left ventricle assist; PulsePump, a pulsating flow for heart and lung machines; and Sternal Prosthesis for fixing the sternum after open-chest surgery. The company was founded in 1999 and is based in Västerås, Sweden.
Full company profileReal Heart financial statements
Real Heart annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 133K | 775K | 111K | 0.00 | 0.00 | 0.00 | 10.0K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -3.80M | -1.43M | -1.93M | 3.96M | 333K | 7.20M | 12.3M | -50.2M | -165K | -246K |
| Operating Income | -3.80M | -9.97M | -8.52M | -7.09M | -8.64M | -10.3M | -13.9M | -17.5M | -15.1M | -15.3M |
| EBITDA | -3.72M | -13.5M | -8.53M | -6.83M | -8.37M | -10.1M | -13.7M | -67.3M | -33.5M | -15.1M |
| Net Income | -3.88M | -13.7M | -8.86M | -7.29M | -8.82M | -10.5M | -14.0M | -68.0M | -34.4M | -35.5M |
| EPS | -0.21 | -0.60 | -0.40 | -26 | -25 | -0.21 | -19 | -47 | -17 | -7.08 |
| Balance Sheet | ||||||||||
| Total Assets | 20.2M | 34.0M | 27.4M | 66.6M | 78.0M | 118M | 120M | 103M | 83.3M | 72.7M |
| Total Liabilities | 4.01M | 6.44M | 8.12M | 7.61M | 6.35M | 6.53M | 22.2M | 20.6M | 15.9M | 10.2M |
| Shareholders' Equity | 16.2M | 27.5M | 19.3M | 59.0M | 71.7M | 111M | 97.6M | 82.0M | 67.3M | 62.5M |
| Cash & Short-term Investments | 8.77M | 17.4M | 3.68M | 25.4M | 22.5M | 42.7M | 11.3M | 43.3M | 23.7M | 16.6M |
| Total Debt | 2.57M | 4.00M | 4.00M | 3.71M | 3.42M | 2.80M | 2.17M | 8.25M | 6.35M | 4.46M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -3.49M | -9.86M | -6.45M | -7.32M | -9.41M | -9.65M | -7.38M | -25.1M | -13.0M | -15.7M |
| Capital Expenditure | 6.18M | 8.05M | 7.87M | 17.7M | 14.8M | 19.6M | 23.8M | 1.77M | 25.3M | 865K |
| Free Cash Flow | -9.67M | -17.9M | -14.3M | -25.0M | -24.2M | -29.2M | -31.1M | -26.8M | -38.3M | -16.5M |
| Ratios | ||||||||||
| ROE | -24.0% | -49.9% | -45.9% | -12.4% | -12.3% | -9.4% | -14.3% | -82.9% | -51.0% | -56.8% |
| ROA | -19.2% | -40.5% | -32.3% | -10.9% | -11.3% | -8.9% | -11.7% | -66.2% | -41.2% | -48.8% |
| Net Profit Margin | -2,927.5% | -1,773.5% | -7,955.3% | - | - | - | -139,880.0% | - | - | - |
| Debt to Equity | 0.16x | 0.15x | 0.21x | 0.06x | 0.05x | 0.03x | 0.02x | 0.10x | 0.09x | 0.07x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Real Heart dividends
Real Heart has not paid dividends in the last 10 fiscal years.
Last stock split: 1:100 on Nov 21, 2024.
Who owns Real Heart
- Insiders 70.11%
- Institutions 3.58%
- Public & others 26.31%
- Shares outstanding 8.50M
- Free float 5.54M
Real Heart company profile
- Company name
- Real Heart
- Ticker
- HEART.ST
- ISIN
- SE0006256798
- Exchange
- Stockholm Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 18
- Fiscal year end
- December
- Address
- KopparbergsvAegen 6, Västerås, Sweden, 722 13
- Phone
- 46 2 14 75 55 50
- Website
- realheart.se
About Real Heart
Scandinavian Real Heart AB (Publ) engages in the design and development of an artificial heart. The company develops Realheart TAH to treat advanced stage heart failure. It also develops RealVAD for pulsating left ventricle assist; PulsePump, a pulsating flow for heart and lung machines; and Sternal Prosthesis for fixing the sternum after open-chest surgery. The company was founded in 1999 and is based in Västerås, Sweden.
Real Heart management
5- Dr. Azad NajarFounder, Chief Innovation Officer, Head of Product Development & Innovation and Director · born 1968
- Dr. Ina Laura PerkinsMD & CEO
- Mr. Jimmy NybomChief Financial Officer · born 1978
- Mr. Thomas FinocchiaroChief Technology Officer · born 1976
- Dr. Ulf KjellmanChief Medical Officer & Member of Medical Advisory Board